Access the full text.
Sign up today, get DeepDyve free for 14 days.
References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.
This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables. Abstract Monoclonal antibodies directed against specific T-lymphocyte antigens, donor-specific blood transfusions, and cyclosporine are permitting many patients to be successfully transplanted with poorly matched kidneys, according to reports at a recent National Kidney Foundation meeting in Washington, DC. Thus, use of these methods is further improving graft survival rates. (Even between 1977 and 1980—before these methods came into general use—graft survival rates increased substantially. In an interview with JAMA MEDICAL NEWS, Henry Krakauer, MD, PhD, noted that rates increased from 52% to 61% at one year for cadaveric transplants and from 70% to 82% for grafts from living related donors. Krakauer, of the Genetics and Transplantation Branch, National Institute of Allergy and Infectious Diseases, Bethesda, Md, derived his figures from various sources, including raw data from the Health Care Financing Administration.) Because mature T lymphocytes appear to be the principal effector cells in most cases of graft rejection, eliminating or suppressing
JAMA – American Medical Association
Published: May 6, 1983
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.